{"product_id":"jnj-bcg-matrix","title":"Johnson \u0026 Johnson Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eJohnson \u0026amp; Johnson sits at an interesting crossroads — a mix of global powerhouses, niche healers, and a few units that need hard choices. Our quick read shows where market share and growth collide, but it’s just the surface. Buy the full BCG Matrix to get quadrant-by-quadrant placement, data-backed recommendations, and an executable plan. Get the complete Word + Excel package and move from insight to action fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDarzalex (multiple myeloma)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDarzalex is the leader in the fast-growing multiple myeloma segment with strong clinical pull, reporting roughly $7.9B in 2024 sales and high-teens percentage year-over-year growth as usage deepens across lines of therapy. It keeps taking share as frontline and combination regimens expand, but growth remains capital-intensive with elevated reinvestment needs. Hold the line: sustained reinvestment can compound Darzalex into a powerhouse cash engine for J\u0026amp;J.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTremfya (immunology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTremfya is gaining ground in psoriasis and psoriatic arthritis with clean Phase 3 and real‑world tolerability and simple dosing, helping it capture significant switch share; 2024 global sales reached about $4.1 billion while the psoriasis biologics category is ~22 billion USD and still expanding. Marketing and access spend remain justified—continued investment to fuel uptake is critical to cement leadership before new rivals enter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCarvykti (CAR-T, myeloma)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCarvykti sits in the Stars quadrant as explosive demand drives rapid uptake: CARTITUDE-1 showed an overall response rate ~98% with deep, durable remissions, attracting clinicians and payers and creating a market accelerating into 2024. Limited direct CAR-T peers in myeloma and strong real-world adoption support defendable share if capacity scales. Johnson \u0026amp; Johnson should invest heavily in manufacturing and cold-chain logistics to unlock the full commercial curve. Capacity ramping and site activation are the key value levers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpsumit \u0026amp; Uptravi (pulmonary hypertension)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOpsumit and Uptravi sit in a durable, expanding PAH niche where prevalence is estimated at 15–50 cases per million and incidence 2–7 per million annually, supporting steady patient-level demand in 2024. Strong physician loyalty and real-world outcome data have sustained market share gains and adherence. The franchise’s breadth across prostacyclin and endothelin mechanisms plus ongoing lifecycle and access programs continue to drive uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDurable niche: PAH prevalence 15–50\/million (2024)\u003c\/li\u003e\n\u003cli\u003eDefensive factors: physician loyalty, real-world outcomes\u003c\/li\u003e\n\u003cli\u003eBreadth: multiple lines\/mechanisms (prostacyclin, endothelin)\u003c\/li\u003e\n\u003cli\u003eSupport: lifecycle management and access programs maintaining growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosense Webster (AFib ablation)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiosense Webster is the category leader in electrophysiology mapping and AFib ablation within Johnson \u0026amp; Johnson, benefiting from secular tailwinds as AFib affects ~6 million Americans and an estimated 59 million people globally; procedure volumes and tech adoption have continued upward into 2024. High switching costs, strong ecosystem integration, and entrenched training programs protect share; continued investment in innovation and operator training widens the moat.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket position: leader in EP mapping and ablation\u003c\/li\u003e\n\u003cli\u003eDemand drivers: AFib prevalence ~6M US, ~59M global\u003c\/li\u003e\n\u003cli\u003eGrowth: rising procedure volumes and adoption in 2024\u003c\/li\u003e\n\u003cli\u003eMoat: ecosystem, training, high switching costs; back R\u0026amp;D\/training\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e7.9B\u003c\/strong\u003e, \u003cstrong\u003e~98%\u003c\/strong\u003e ORR, AFib \u003cstrong\u003e6M\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Darzalex $7.9B (2024) with high‑teens growth; Tremfya $4.1B (2024) capturing psoriasis share; Carvykti ~98% ORR driving rapid CAR-T uptake; Biosense Webster benefits from AFib prevalence ~6M US\/59M global; Opsumit\/Uptravi serve PAH niche (15–50\/million).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024\/$\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDarzalex\u003c\/td\u003e\n\u003ctd\u003e7.9B\u003c\/td\u003e\n\u003ctd\u003eHigh‑teens % growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTremfya\u003c\/td\u003e\n\u003ctd\u003e4.1B\u003c\/td\u003e\n\u003ctd\u003eLarge psoriasis share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCarvykti\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~98% ORR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosense\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eAFib 6M US\/59M global\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG analysis of Johnson \u0026amp; Johnson products: stars, cash cows, question marks and dogs with investment, divestment and risk guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Johnson \u0026amp; Johnson BCG Matrix highlighting business pain points for quick C-level decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStelara (immunology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStelara (ustekinumab) sits on a massive, high-margin base—generating roughly $8 billion in 2023—and dominates a mature immunology segment. Growth is moderating to low-single-digit rates as LOE dynamics and regional competitive entry approach. It continues to throw off substantial cash with modest promotion, so J\u0026amp;J can milk near-term cashflows while steering patients toward next-generation assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXarelto (anticoagulant, U.S.)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXarelto remains a large-scale, high-share U.S. anticoagulant with estimated 2024 U.S. sales around $3.4 billion and a sticky script base despite DOAC competition. Promotion needs are lower as patient persistence and refill rates keep cash conversion strong; gross-to-net dynamics remain favorable. Focus on optimizing contracting, rebates and defending cardiology and primary-care prescriber cohorts to protect margin and share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEthicon Surgical (stapling \u0026amp; energy)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEthicon Surgical (stapling \u0026amp; energy) is J\u0026amp;J’s core surgical toolkit, leveraging entrenched hospital relationships and long procurement contracts. The stapling and energy markets are mature, procurement-driven and predictably cyclical. Scale and manufacturing efficiency generate steady cash flow for Medical Devices. Ongoing incremental product innovation and robust field support sustain high utilization and repeat purchasing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDePuy Synthes (hips, knees, trauma)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDePuy Synthes leverages a significant installed base and strong surgeon loyalty across hips, knees and trauma, underpinning steady demand; J\u0026amp;J Medical Devices reported roughly $24.6 billion in 2024, with orthopedics a major contributor. Mix shifts and pricing pressure are manageable given scale and distribution reach, keeping margins resilient. Cash flow remains reliable despite modest procedure growth; focus is on ops excellence and selective premiumization to sustain returns.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstalled base: durable market position\u003c\/li\u003e\n\u003cli\u003e2024 Med Devices rev: ~$24.6B\u003c\/li\u003e\n\u003cli\u003eScale offsets pricing\/mix pressure\u003c\/li\u003e\n\u003cli\u003eReliable cash flow with modest volume growth\u003c\/li\u003e\n\u003cli\u003eStrategy: ops excellence + targeted premiumization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eACUVUE (vision care)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eACUVUE is a cash cow for Johnson \u0026amp; Johnson, holding a leading share in the global soft contact lens category with strong brand equity and deep retail and professional channels that keep churn low; marketing spend is moderate relative to margins. Tight inventory management, incremental material and wear-time innovations, and steady distribution pricing maximize free cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-share brand\u003c\/li\u003e\n\u003cli\u003eLow churn via channel depth\u003c\/li\u003e\n\u003cli\u003eModerate marketing intensity\u003c\/li\u003e\n\u003cli\u003eKeep supply tight\u003c\/li\u003e\n\u003cli\u003eInnovate edges\u003c\/li\u003e\n\u003cli\u003eLet cash roll\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-margin biologics, sticky Rx cash and \u003cstrong\u003e$24.6B\u003c\/strong\u003e med-device scale fund R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStelara generates very high-margin cash from a mature immunology base, allowing J\u0026amp;J to fund next-gen programs while growth moderates.\u003c\/p\u003e\n\u003cp\u003eXarelto (~$3.4B U.S. 2024) delivers sticky prescription cash with low promo intensity and focus on contracting to defend margins.\u003c\/p\u003e\n\u003cp\u003eEthicon\/DePuy within Med Devices (2024 rev ~24.6B) provide steady, procurement-driven cash via installed bases and scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStelara\u003c\/td\u003e\n\u003ctd\u003ehigh-$bn\u003c\/td\u003e\n\u003ctd\u003eCash cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXarelto\u003c\/td\u003e\n\u003ctd\u003e$3.4B (US)\u003c\/td\u003e\n\u003ctd\u003eCash cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed Devices\u003c\/td\u003e\n\u003ctd\u003e$24.6B\u003c\/td\u003e\n\u003ctd\u003eCash generator\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eACUVUE\u003c\/td\u003e\n\u003ctd\u003emajor revenue\u003c\/td\u003e\n\u003ctd\u003eStable cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eJohnson \u0026amp; Johnson BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Johnson \u0026amp; Johnson BCG Matrix you're previewing is the exact file you'll receive after purchase. No watermarks, no placeholders—just the fully formatted strategic matrix tailored to J\u0026amp;J's portfolio. It’s ready to edit, print, or present straight away, backed by clear market insights and professional layout. Buy once, download instantly—no surprises, just actionable clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56164181082489,"sku":"jnj-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/jnj-bcg-matrix.png?v=1762726835","url":"https:\/\/portersfiveforce.com\/products\/jnj-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}